Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 5/20 | 0.40 |
| ▸ | MGLL | Q99685 | 5/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | MIF | P14174 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | DRD2 | P14416 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | BRD4 | O60885 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14750017 | 0.88 | DGAT1 (0.39) | DGAT1MGLLTDP1MAPTMEN1 | |
| SCHEMBL14749776 | 0.86 | L3MBTL1 (0.42) | ALDH1A1GAASMN1; SMN2L3MBTL1MAPT | |
| SCHEMBL14750025 | 0.78 | MGLL (0.41) | DGAT1MGLL | |
| SCHEMBL14749736 | 0.76 | ALDH1A1 (0.48) | ALDH1A1GAAMEN1KMT2AMIF | |
| SCHEMBL14734815 | 0.74 | KDR (0.38) | DGAT1 | |
| SCHEMBL16784835 | 0.74 | SMN1; SMN2 (0.53) | TDP1ALDH1A1GAASMN1; SMN2L3MBTL1 | |
| SCHEMBL14750672 | 0.73 | TDP1 (0.41) | TDP1ALDH1A1GAASMN1; SMN2L3MBTL1 | |
| SCHEMBL14734749 | 0.72 | PDE4D (0.39) | ALDH1A1SMN1; SMN2MEN1KMT2AHPGD | |
| SCHEMBL17599609 | 0.70 | ALDH1A1 (0.50) | ALDH1A1GAASMN1; SMN2MEN1KMT2A | |
| SCHEMBL14749777 | 0.70 | CYP2C9 (0.55) | DGAT1TDP1ALDH1A1GAASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9051290-B2 | Biaryl phosphodiesterase inhibitors | LEO PHARMA A/S (DK) | 2015-06-09 | — | — | US | disclosed |
| US-20130059853-A1 | BIARYL PHOSPHODIESTERASE INHIBITORS | LEO PHARMA A/S (DK) | 2013-03-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130059853-A1 | BIARYL PHOSPHODIESTERASE INHIBITORS | PDE3B, PDE3A, PDE4A | DGAT1 942/4885MGLL 254/4885TDP1 49/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.